{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:47:08Z","timestamp":1761709628403},"reference-count":29,"publisher":"Pharmaceutical Society of Japan","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2019,8,1]]},"DOI":"10.1248\/bpb.b18-00984","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T22:03:20Z","timestamp":1564610600000},"page":"1295-1302","source":"Crossref","is-referenced-by-count":16,"title":["Cranberry Attenuates Progression of Non-alcoholic Fatty Liver Disease Induced by High-Fat Diet in Mice"],"prefix":"10.1248","volume":"42","author":[{"given":"Kahori","family":"Shimizu","sequence":"first","affiliation":[{"name":"Laboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe","family":"Ono","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Faculty of Pharmacy, Osaka Ohtani University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akane","family":"Imoto","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Nagayama","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naho","family":"Tetsumura","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Terada","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Tomita","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Faculty of Pharmacy, Osaka Ohtani University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Nishinaka","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, Marczak L, Mokdad AH, Moradi-Lakeh M, Naghavi M, Salama JS, Vos T, Abate KH, Abbafati C, Ahmed MB, Al-Aly Z, Alkerwi A, Al-Raddadi R, Amare AT, Amberbir A, Amegah AK, Amini E, Amrock SM, Anjana RM, Arnlov J, Asayesh H, Banerjee A, Barac A, Baye E, Bennett DA, Beyene AS, Biadgilign S, Biryukov S, Bjertness E, Boneya DJ, Campos-Nonato I, Carrero JJ, Cecilio P, Cercy K, Ciobanu LG, Cornaby L, Damtew SA, Dandona L, Dandona R, Dharmaratne SD, Duncan BB, Eshrati B, Esteghamati A, Feigin VL, Fernandes JC, Furst T, Gebrehiwot TT, Gold A, Gona PN, Goto A, Habtewold TD, Hadush KT, Hafezi-Nejad N, Hay SI, Horino M, Islami F, Kamal R, Kasaeian A, Katikireddi SV, Kengne AP, Kesavachandran CN, Khader YS, Khang YH, Khubchandani J, Kim D, Kim YJ, Kinfu Y, Kosen S, Ku T, Defo BK, Kumar GA, Larson HJ, Leinsalu M, Liang X, Lim SS, Liu P, Lopez AD, Lozano R, Majeed A, Malekzadeh R, Malta DC, Mazidi M, McAlinden C, McGarvey ST, Mengistu DT, Mensah GA, Mensink GBM, Mezgebe HB, Mirrakhimov EM, Mueller UO, Noubiap JJ, Obermeyer CM, Ogbo FA, Owolabi MO, Patton GC, Pourmalek F, Qorbani M, Rafay A, Rai RK, Ranabhat CL, Reinig N, Safiri S, Salomon JA, Sanabria JR, Santos IS, Sartorius B, Sawhney M, Schmidhuber J, Schutte AE, Schmidt MI, Sepanlou SG, Shamsizadeh M, Sheikhbahaei S, Shin MJ, Shiri R, Shiue I, Roba HS, Silva DAS, Silverberg JI, Singh JA, Stranges S, Swaminathan S, Tabares-Seisdedos R, Tadese F, Tedla BA, Tegegne BS, Terkawi AS, Thakur JS, Tonelli M, Topor-Madry R, Tyrovolas S, Ukwaja KN, Uthman OA, Vaezghasemi M, Vasankari T, Vlassov VV, Vollset SE, Weiderpass E, Werdecker A, Wesana J, Westerman R, Yano Y, Yonemoto N, Yonga G, Zaidi Z, Zenebe ZM, Zipkin B, Murray CJL. Health Effects of overweight and obesity in 195 countries over 25 years. <i>N. Engl. J. Med.<\/i>, <b>377<\/b>, 13\u201327 (2017)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kahn BB, Flier JS. Obesity and insulin resistance. <i>J. Clin. Invest.<\/i>, <b>106<\/b>, 473\u2013481 (2000).","DOI":"10.1172\/JCI10842"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. <i>Cell<\/i>, <b>104<\/b>, 531\u2013543 (2001).","DOI":"10.1016\/S0092-8674(01)00240-9"},{"key":"4","unstructured":"4) Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. <i>Am. J. Gastroenterol.<\/i>, <b>96<\/b>, 2957\u20132961 (2001)."},{"key":"5","unstructured":"5) Fu JF, Shi HB, Liu LR, Jiang P, Liang L, Wang CL, Liu XY. Non-alcoholic fatty liver disease: an early mediator predicting metabolic syndrome in obese children? <i>World J. Gastroenterol.<\/i>, <b>17<\/b>, 735\u2013742 (2011)."},{"key":"6","unstructured":"6) Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>Hepatology<\/i>, <b>55<\/b>, 2005\u20132023 (2012)."},{"key":"7","unstructured":"7) McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. <i>J. Hepatol.<\/i>, <b>62<\/b>, 1148\u20131155 (2015)."},{"key":"8","unstructured":"8) Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology<\/i>, <b>67<\/b>, 328\u2013357 (2018)."},{"key":"9","unstructured":"9) Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. <i>Science<\/i>, <b>332<\/b>, 1519\u20131523 (2011)."},{"key":"10","unstructured":"10) Byrne CD, Targher G. NAFLD: a multisystem disease. <i>J. Hepatol.<\/i>, <b>62<\/b> (Suppl.), S47\u2013S64 (2015)."},{"key":"11","unstructured":"11) Day CP, James OF. Steatohepatitis: a tale of two \u201chits\u201d? <i>Gastroenterology<\/i>, <b>114<\/b>, 842\u2013845 (1998)."},{"key":"12","unstructured":"12) Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. <i>Hepatology<\/i>, <b>52<\/b>, 1836\u20131846 (2010)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). <i>Metabolism<\/i>, <b>65<\/b>, 1038\u20131048 (2016).","DOI":"10.1016\/j.metabol.2015.12.012"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. <i>J. Clin. Invest.<\/i>, <b>114<\/b>, 1752\u20131761 (2004).","DOI":"10.1172\/JCI200421625"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. <i>Life Sci.<\/i>, <b>84<\/b>, 705\u2013712 (2009).","DOI":"10.1016\/j.lfs.2009.02.026"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. <i>Am. J. Gastroenterol.<\/i>, <b>98<\/b>, 2485\u20132490 (2003).","DOI":"10.1111\/j.1572-0241.2003.08699.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Blumberg JB, Camesano TA, Cassidy A, Kris-Etherton P, Howell A, Manach C, Ostertag LM, Sies H, Skulas-Ray A, Vita JA. Cranberries and their bioactive constituents in human health. <i>Adv. Nutr.<\/i>, <b>4<\/b>, 618\u2013632 (2013).","DOI":"10.3945\/an.113.004473"},{"key":"18","unstructured":"18) Vinson JA, Su X, Zubik L, Bose P. Phenol antioxidant quantity and quality in foods: fruits. <i>J. Agric. Food Chem.<\/i>, <b>49<\/b>, 5315\u20135321 (2001)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Ariga T. The antioxidative function, preventive action on disease and utilization of proanthocyanidins. <i>Biofactors<\/i>, <b>21<\/b>, 197\u2013201 (2004).","DOI":"10.1002\/biof.552210140"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Glisan SL, Ryan C, Neilson AP, Lambert JD. Cranberry extract attenuates hepatic inflammation in high-fat-fed obese mice. <i>J. Nutr. Biochem.<\/i>, <b>37<\/b>, 60\u201366 (2016).","DOI":"10.1016\/j.jnutbio.2016.07.009"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Anh\u00ea FF, Nachbar RT, Varin TV, Vilela V, Dudonn\u00e9 S, Pilon G, Fournier M, Lecours MA, Desjardins Y, Roy D, Levy E, Marette A. A polyphenol-rich cranberry extract reverses insulin resistance and hepatic steatosis independently of body weight loss. <i>Molecular Metabolism<\/i>, <b>6<\/b>, 1563\u20131573 (2017).","DOI":"10.1016\/j.molmet.2017.10.003"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Kim MJ, Chung JY, Kim JH, Kwak HK. Effects of cranberry powder on biomarkers of oxidative stress and glucose control in d<i>b<\/i>\/d<i>b<\/i> mice. <i>Nutr. Res. Pract.<\/i>, <b>7<\/b>, 430\u2013438 (2013).","DOI":"10.4162\/nrp.2013.7.6.430"},{"key":"23","unstructured":"23) Pettinelli P, Videla LA. Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. <i>J. Clin. Endocrinol. Metab.<\/i>, <b>96<\/b>, 1424\u20131430 (2011)."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjoro K, Aukrust P. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. <i>J. Hepatol.<\/i>, <b>44<\/b>, 1167\u20131174 (2006).","DOI":"10.1016\/j.jhep.2006.02.011"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, Klein S. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>106<\/b>, 15430\u201315435 (2009).","DOI":"10.1073\/pnas.0904944106"},{"key":"26","unstructured":"26) Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. <i>J. Clin. Invest.<\/i>, <b>109<\/b>, 1125\u20131131 (2002)."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa T, Amemiya-Kudo M, Tomita S, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Nagai R, Ishibashi S, Yamada N. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)\/Lep(ob) mice. <i>J. Biol. Chem.<\/i>, <b>277<\/b>, 19353\u201319357 (2002).","DOI":"10.1074\/jbc.M201584200"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. <i>Free Radic. Biol. Med.<\/i>, <b>52<\/b>, 59\u201369 (2012).","DOI":"10.1016\/j.freeradbiomed.2011.10.003"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Okuno Y, Fukuhara A, Hashimoto E, Kobayashi H, Kobayashi S, Otsuki M, Shimomura I. Oxidative stress inhibits healthy adipose expansion through suppression of SREBF1-mediated lipogenic pathway. <i>Diabetes<\/i>, <b>67<\/b>, 1113\u20131127 (2018).","DOI":"10.2337\/db17-1032"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/8\/42_b18-00984\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T03:22:28Z","timestamp":1564802548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/8\/42_b18-00984\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b18-00984","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,1]]}}}